Overview
UroGen Q2 JELMYTO revenue grows 11% yr/yr, beating analyst expectations
FDA approves ZUSDURI, marking a milestone in UroGen's product portfolio
Net loss for Q2 misses analyst estimates due to increased R&D and SG&A expenses
Outlook
Company expects full-year 2025 JELMYTO revenue of $94 to $98 mln
UroGen anticipates 2025 operating expenses of $215 to $225 mln
Company sees $5 bln+ market opportunity for ZUSDURI
UroGen aims to support ZUSDURI launch and drive sustained growth
Result Drivers
DEMAND GROWTH - JELMYTO sales increased 11% year-over-year, driven by 7% demand growth and favorable pricing
R&D - Expenses for the second quarter of 2025 were $18.9 million, including non-cash share-based compensation expense of $0.4 million
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $24.22 mln | $23.10 mln (8 Analysts) |
Q2 Net Income | Miss | -$49.94 mln | -$40 mln (7 Analysts) |
Q2 Operating Income | Miss | -$41.45 mln | -$33.50 mln (8 Analysts) |
Q2 Pretax Profit | Miss | -$48.92 mln | -$40.40 mln (7 Analysts) |
Q2 Basic EPS | -$1.05 | ||
Q2 Operating Expenses | $62.11 mln |
Press Release: ID:nGNX3q8q7C
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)